Icosavax, Inc.
icosavax.comNo Longer Reporting
The company has not filed an annual or quarterly report since its Q3 FY2023 10-Q, filed Nov 14, 2023. Its latest SEC filing is a 15-12G from Mar 1, 2024.
10-Q for Q3 FY2023, filed Nov 14, 2023
The sections below describe the company as of the FY2022 annual report.
What Did They Do?
Develops particle-based vaccine candidates for infectious diseases, focusing on respiratory illnesses in older adults, including respiratory syncytial virus and human metapneumovirus.
10-K for FY2022, filed Mar 30, 2023
How Did They Make Money?
Grant funding reimbursed certain development costs; it became revenue when the grant's conditions were met, and the company had no vaccine-product sales.
10-K for FY2022, filed Mar 30, 2023The Company’s revenue consists of revenue under its prior Grant Agreement with BMGF (see Note 4). The Company was reimbursed for certain…View ↗
To date, we have not generated any revenues from the commercial sale of approved products, and we do not expect to generate revenues from…View ↗
Based on our current operating plan, we believe that our existing cash, cash equivalents, restricted cash, and short-term investments will…View ↗
$582K
-
10-K for FY2022, filed Mar 30, 2023
$582K ↗
Did Revenues Turn Into Profits?
No. It lost $91.8M in FY2022.
10-K for FY2022, filed Mar 30, 2023
−$95.1MView ↗
10-K for FY2022, filed Mar 30, 2023
−$91.8MView ↗
10-K for FY2022, filed Mar 30, 2023
−$72.8MView ↗
How Were They Changing?
- Net income
-
Sources
10-Q for Q3 FY2023, filed Nov 14, 2023
−$22MView ↗
- ▲ 0% (Loss)
- vs −$22M in Q3 FY2022
-
Feb 20, 2024
AstraZeneca completed its acquisition of Icosavax
Icosavax became a wholly owned subsidiary, and the offer included a contingent value right.
Sources
8-K, filed Feb 20, 2024
Pursuant to the Merger Agreement, and upon the terms and subject to the conditions thereof, on December 27, 2023, Merger Sub commenced a…View ↗
-
Dec 12, 2023
AstraZeneca agreed to acquire Icosavax
The offer combined cash consideration with a contingent value right tied to vaccine approval and sales milestones.
Sources
8-K, filed Dec 12, 2023
On December 11, 2023, Icosavax, Inc., a Delaware corporation (the Company or Icosavax), entered into an Agreement and Plan of Merger (the…View ↗
Who Did They Compete With?
Competes with GlaxoSmithKline, Merck, Sanofi, Pfizer, Moderna, CSL Bering, VBI Vaccines, SpyBiotech, ModeX, UVax Bio, Bavarian Nordic, Janssen, Seqirus, Novavax, AstraZeneca, and BioNTech
10-K for FY2022, filed Mar 30, 2023Our industry is highly competitive and subject to rapid and significant regulatory and technological change. The current vaccine market is…View ↗
Loading...
